Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria.

H Bukirwa, L Orton
Author Information
  1. H Bukirwa: Uganda Malaria Surveillance Project, Mulago Hospital Complex, Kampala, Uganda, PO BOX 24943. hbukirwa@hotmail.com

Abstract

BACKGROUND: Multiple-drug-resistant malaria is widespread, and in South-East Asia resistance is high against nearly all single therapy antimalarial drugs. Here, and in other areas with low malaria transmission, the combination of artesunate and mefloquine may provide an effective alternative.
OBJECTIVES: To compare artesunate plus mefloquine with mefloquine alone for treating uncomplicated Plasmodium falciparum malaria.
SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register (May 2005), CENTRAL (The Cochrane Library Issue 2, 2005), MEDLINE (1966 to May 2005), EMBASE (1988 to May 2005), LILACS (May 2005), BIOSIS (1985 to June 2005), conference proceedings, and reference lists. We also contacted researchers, organizations, and pharmaceutical companies.
SELECTION CRITERIA: Randomized and quasi-randomized controlled trials comparing artesunate plus mefloquine with mefloquine alone for treating uncomplicated malaria.
DATA COLLECTION AND ANALYSIS: Two authors independently applied the inclusion criteria, extracted data, and assessed methodological quality. The primary outcome was treatment failure by day 28, defined as evidence of parasitaemia with or without clinical failure between days zero (start of treatment) and 28. For dichotomous data we calculated relative risks (RR) and 95% confidence intervals (CI).
MAIN RESULTS: Eight trials involving 1996 participants met the inclusion criteria. All were conducted in areas with low malaria transmission, seven in South-East Asia and one in the Peruvian Amazon. The doses and dosing regimens of artesunate and mefloquine varied across trials. The trials using a total dose of 25 mg/kg mefloquine and 10 mg artesunate reported fewer treatment failures with the combination at all time points: day 28 (RR 0.17, 95% CI 0.06 to 0.47; 824 participants, 4 trials), day 42 (RR 0.23, 95% CI 0.14 to 0.39; 298 participants, 1 trial), and day 63 (RR 0.26, 95% CI 0.09 to 0.77; 501 participants, 2 trials). The results for parasitaemia showed a similar trend. Trials using a lower dose of artesunate tended to favour the artesunate plus mefloquine combination. Overall, adverse events were similar across treatment arms.
AUTHORS' CONCLUSIONS: Artesunate plus mefloquine performs better than mefloquine alone for treating uncomplicated falciparum malaria in areas with low malaria transmission. A total dose of 25 mg/kg mefloquine and at least 10 mg artesunate leads to higher cure rates. Better reporting of methods and standardisation of outcomes would help the interpretation of future trials.

References

  1. Ann Trop Paediatr. 2001 Dec;21(4):307-12 [PMID: 11732148]
  2. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):523-7 [PMID: 8560531]
  3. Lancet. 1999 Jun 5;353(9168):1965-7 [PMID: 10371589]
  4. Lancet. 1996 Nov 2;348(9036):1184-5 [PMID: 8898030]
  5. JAMA. 1996 Jan 17;275(3):230-3 [PMID: 8604177]
  6. Cochrane Database Syst Rev. 2000;(2):CD000527 [PMID: 10796551]
  7. Cochrane Database Syst Rev. 2000;(2):CD000256 [PMID: 10796519]
  8. Antimicrob Agents Chemother. 1997 Jul;41(7):1413-22 [PMID: 9210658]
  9. Lancet Infect Dis. 2002 Apr;2(4):209-18 [PMID: 11937421]
  10. Wilderness Environ Med. 1995 Aug;6(3):307-24 [PMID: 11990096]
  11. Lancet. 1992 Apr 4;339(8797):821-4 [PMID: 1347854]
  12. Parasitology. 2000 Sep;121 ( Pt 3):237-46 [PMID: 11085244]
  13. Trans R Soc Trop Med Hyg. 1997 Mar-Apr;91(2):195-8 [PMID: 9196768]
  14. Ann Trop Med Parasitol. 1994 Apr;88(2):131-6 [PMID: 8067808]
  15. Southeast Asian J Trop Med Public Health. 1998 Jun;29(2):344-54 [PMID: 9886126]
  16. Am J Trop Med Hyg. 2003 May;68(5):608-12 [PMID: 12812355]
  17. Am J Trop Med Hyg. 2003 Jan;68(1):107-10 [PMID: 12557835]
  18. BMJ. 2001 Jul 7;323(7303):42-6 [PMID: 11440947]
  19. Southeast Asian J Trop Med Public Health. 1992 Dec;23(4):621-34 [PMID: 1298068]
  20. Trop Med Int Health. 2004 Nov;9(11):1184-90 [PMID: 15548314]
  21. Am J Trop Med Hyg. 1991 Jul;45(1):86-91 [PMID: 1867351]
  22. Bull World Health Organ. 1994;72(1):83-7 [PMID: 8131255]
  23. Trans R Soc Trop Med Hyg. 1994 Mar-Apr;88(2):213-7 [PMID: 8036679]
  24. Ann Trop Med Parasitol. 2005 Mar;99(2):111-7 [PMID: 15814029]
  25. Southeast Asian J Trop Med Public Health. 1997 Sep;28(3):465-71 [PMID: 9561593]
  26. Rev Soc Bras Med Trop. 1996 May-Jun;29(3):251-7 [PMID: 8701045]
  27. Lancet. 1996 Jun 15;347(9016):1654-8 [PMID: 8642959]
  28. J Infect Dis. 1994 Oct;170(4):971-7 [PMID: 7930743]
  29. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S33-6 [PMID: 8053022]
  30. Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):207-11 [PMID: 9764335]

MeSH Term

Antimalarials
Artemisinins
Artesunate
Drug Therapy, Combination
Humans
Malaria, Falciparum
Mefloquine
Sesquiterpenes

Chemicals

Antimalarials
Artemisinins
Sesquiterpenes
Artesunate
Mefloquine

Word Cloud

Created with Highcharts 10.0.0mefloquine0malariaartesunatetrials2005plustreatinguncomplicatedMaytreatmentdayRR95%CIparticipantsareaslowtransmissioncombinationalone28doseSouth-EastAsiafalciparumCochrane2inclusioncriteriadatafailureparasitaemiaacrossusingtotal25mg/kg10mgsimilarArtesunateBACKGROUND:Multiple-drug-resistantwidespreadresistancehighnearlysingletherapyantimalarialdrugsmayprovideeffectivealternativeOBJECTIVES:comparePlasmodiumSEARCHSTRATEGY:searchedInfectiousDiseasesGroupSpecializedRegisterCENTRALLibraryIssueMEDLINE1966EMBASE1988LILACSBIOSIS1985JuneconferenceproceedingsreferencelistsalsocontactedresearchersorganizationspharmaceuticalcompaniesSELECTIONCRITERIA:Randomizedquasi-randomizedcontrolledcomparingDATACOLLECTIONANDANALYSIS:TwoauthorsindependentlyappliedextractedassessedmethodologicalqualityprimaryoutcomedefinedevidencewithoutclinicaldayszerostartdichotomouscalculatedrelativerisksconfidenceintervalsMAINRESULTS:Eightinvolving1996metconductedsevenonePeruvianAmazondosesdosingregimensvariedreportedfewerfailurestimepoints:1706478244422314392981trial63260977501resultsshowedtrendTrialslowertendedfavourOveralladverseeventsarmsAUTHORS'CONCLUSIONS:performsbetterleastleadshighercureratesBetterreportingmethodsstandardisationoutcomeshelpinterpretationfutureversus

Similar Articles

Cited By